B of A Securities Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $47
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
B of A Securities analyst Daniel Giraldo initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces Price Target of $47.
B of A Securities analyst Daniel Giraldo initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces Price Target of $47.
